MedTrace Logo

A Randomized Phase 1 of of MZE001 in Healthy Volunteers

NCT05249621 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2023-02-06

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single (SAD) / multiple (MAD) ascending dose and food effect study.

Conditions

  • Healthy

Interventions

DRUG

MZE001

Small molecule inhibitor of muscle glycogen synthase

DRUG

Placebo

Product containing excipients with no active ingredients

Sponsors & Collaborators

  • Maze Therapeutics

    lead INDUSTRY

Principal Investigators

  • Sarah Noonberg, MD · Maze Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2022-12-21
Completion
2022-12-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05249621 on ClinicalTrials.gov